Deutsche Bank Ag\ Arvinas, Inc. Transaction History

Deutsche Bank Ag\

$245 Billion
Q1 2025

A detailed history of Deutsche Bank Ag\ transactions in Arvinas, Inc. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 228,633 shares of ARVN stock, worth $1.72 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

228,633

Previous 217,220 5.25%

Holding current value

$1.72 Million

Previous $4.16 Million 61.46%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 09, 2025	BUY	$7.02 - $20.5 $80,119 - $233,966	11,413 Added 5.25%	228,633 $1.61 Million
Q4 2024 Feb 14, 2025	SELL	$17.83 - $28.04 $234,749 - $369,174	-13,166 Reduced 5.71%	217,220 $4.16 Million
Q3 2024 Jun 26, 2025	BUY	$23.66 - $32.73 $41,475 - $57,375	1,753 Added 0.77%	230,386 $5.67 Million
Q3 2024 Nov 13, 2024	BUY	$23.66 - $32.73 $1.04 Million - $1.44 Million	43,979 Added 23.59%	230,386 $5.67 Million
Q2 2024 Jun 12, 2025	SELL	$24.46 - $40.4 $1.03 Million - $1.71 Million	-42,226 Reduced 18.47%	186,407 $4.96 Million
Q2 2024 Aug 14, 2024	BUY	$24.46 - $40.4 $1.26 Million - $2.08 Million	51,452 Added 38.13%	186,407 $4.96 Million
Q1 2024 Jun 02, 2025	SELL	$36.38 - $52.31 $3.41 Million - $4.9 Million	-93,678 Reduced 40.97%	134,955 $5.57 Million
Q1 2024 May 15, 2024	BUY	$36.38 - $52.31 $1.78 Million - $2.56 Million	48,959 Added 56.93%	134,955 $5.57 Million
Q4 2023 Feb 14, 2024	BUY	$14.19 - $42.33 $316,167 - $943,154	22,281 Added 34.97%	85,996 $3.54 Million
Q3 2023 Nov 09, 2023	SELL	$19.64 - $28.21 $2.17 Million - $3.12 Million	-110,457 Reduced 63.42%	63,715 $1.25 Million
Q2 2023 Aug 14, 2023	SELL	$21.73 - $31.43 $254,958 - $368,768	-11,733 Reduced 6.31%	174,172 $4.32 Million
Q1 2023 May 15, 2023	BUY	$26.15 - $37.26 $255,328 - $363,806	9,764 Added 5.54%	185,905 $5.08 Million
Q4 2022 Feb 13, 2023	BUY	$32.47 - $57.24 $45,685 - $80,536	1,407 Added 0.81%	176,141 $6.03 Million
Q3 2022 Nov 14, 2022	SELL	$41.87 - $57.99 $1.01 Million - $1.4 Million	-24,169 Reduced 12.15%	174,734 $7.77 Million
Q2 2022 Aug 11, 2022	BUY	$36.01 - $74.24 $953,148 - $1.97 Million	26,469 Added 15.35%	198,903 $8.37 Million
Q1 2022 May 13, 2022	SELL	$60.27 - $81.57 $1.23 Million - $1.66 Million	-20,355 Reduced 10.56%	172,434 $11.6 Million
Q4 2021 Feb 11, 2022	SELL	$65.85 - $96.21 $4.98 Million - $7.28 Million	-75,699 Reduced 28.19%	192,789 $15.8 Million
Q3 2021 Nov 04, 2021	SELL	$73.2 - $107.87 $50.2 Million - $74 Million	-685,703 Reduced 71.86%	268,488 $22.1 Million
Q2 2021 Aug 11, 2021	BUY	$60.45 - $84.26 $47 Million - $65.6 Million	778,093 Added 441.85%	954,191 $73.5 Million
Q1 2021 May 13, 2021	BUY	$58.19 - $91.37 $8.17 Million - $12.8 Million	140,377 Added 392.98%	176,098 $11.6 Million
Q4 2020 Feb 16, 2021	SELL	$20.19 - $84.93 $2.62 Million - $11 Million	-129,976 Reduced 78.44%	35,721 $3.03 Million
Q3 2020 Nov 12, 2020	SELL	$22.99 - $36.34 $4.36 Million - $6.89 Million	-189,504 Reduced 53.35%	165,697 $3.91 Million
Q2 2020 Aug 13, 2020	BUY	$29.88 - $56.74 $10.3 Million - $19.5 Million	343,915 Added 3047.27%	355,201 $11.9 Million
Q1 2020 May 14, 2020	SELL	$33.0 - $54.5 $439,329 - $725,558	-13,313 Reduced 54.12%	11,286 $455,000
Q4 2019 Feb 14, 2020	BUY	$15.39 - $44.38 $295,872 - $853,205	19,225 Added 357.74%	24,599 $1.01 Million
Q3 2019 Nov 14, 2019	SELL	$21.55 - $27.61 $124,041 - $158,923	-5,756 Reduced 51.72%	5,374 $114,000
Q2 2019 Aug 14, 2019	BUY	$15.96 - $23.8 $20,029 - $29,869	1,255 Added 12.71%	11,130 $244,000
Q1 2019 May 15, 2019	SELL	$13.55 - $23.79 $10,392 - $18,246	-767 Reduced 7.21%	9,875 $143,000
Q4 2018 Feb 14, 2019	BUY	$11.19 - $18.56 $119,083 - $197,515	10,642 New	10,642 $135,000

Others Institutions Holding ARVN

# of Institutions

245

Shares Held

62.5M

Call Options Held

2.65M

Put Options Held

1.1M

View Full List

About ARVINAS, INC.

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $401M
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

More about ARVN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Account